Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers

PURPOSE: Nilotinib is a second-generation oral tyrosine kinase inhibitor (TKI) with superior efficacy compared with imatinib mesylate in the treatment of chronic phase chronic myelogenous leukemia (CML). Calcium carbonate is commonly used as a source of calcium supplementation or as antacid to ameli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tawbi, Hussein A., Tran, An L., Christner, Susan M., Lin, Yan, Johnson, Matthew, Mowrey, Emily, Appleman, Leonard R., Stoller, Ronald, Miller, Brian M., Egorin, Merrill J., Beumer, Jan H.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3818249/
https://ncbi.nlm.nih.gov/pubmed/24036846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2283-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados